Turn Therapeutics Inc. filed a Form S-3 registration statement with the SEC on November 9, 2026, covering the potential offering of up to $150,000,000 in aggregate securities and including a separate at-the-market facility of up to $50,000,000 in common stock through TD Securities (USA) LLC.
Key Highlights
- Shelf offering ceiling: The base prospectus covers up to $150,000,000 in aggregate of common stock, preferred stock, debt securities, warrants, rights, and/or units.
- ATM facility: A sales agreement prospectus covers up to $50,000,000 of common stock to be sold from time to time under a sales agreement dated November 9, 2026, with TD Securities (USA) LLC ("TD Cowen").
- Overlap structure: The $50,000,000 ATM amount is included within, not in addition to, the $150,000,000 base shelf amount.
- Recent share price: The closing price of common stock on Nasdaq was $9.48 per share on November 6, 2026, according to the filing.
- Company classification: Turn Therapeutics is identified in the filing as a non-accelerated filer, smaller reporting company, and emerging growth company.
- Exchange listing: Common stock is listed on NASDAQ:TTRX under the symbol "TTRX" on The Nasdaq Global Market.
Turn Therapeutics' Dual-Prospectus Shelf Registration and ATM Sales Agreement
Turn Therapeutics Inc., a Delaware corporation headquartered at 250 N. Westlake Blvd, STE 210, Westlake Village, CA 91362, filed a Form S-3 registration statement on November 9, 2026. According to the filing, the registration statement contains two prospectuses: a base prospectus and a sales agreement prospectus. The base prospectus covers the potential offering of up to $150,000,000 in aggregate of common stock (par value $0.0001 per share), preferred stock, debt securities, warrants, rights, and units, in one or more offerings from time to time at prices and terms to be determined at the time of each offering.
The sales agreement prospectus covers up to $50,000,000 of common stock that may be issued and sold from time to time under a sales agreement, dated November 9, 2026, with TD Securities (USA) LLC ("TD Cowen"). The filing states that the $50,000,000 available under the sales agreement prospectus is included within the $150,000,000 covered by the base prospectus. If the sales agreement is terminated and no shares are sold under it, the full $150,000,000 may be used for other offerings under the base prospectus, subject to applicable limitations stated in the filing.
The filing notes that securities may be offered and sold through underwriters, brokers, dealers, or agents, or directly to purchasers, with specific terms to be provided in prospectus supplements. Bradley Burnam is named as Chief Executive Officer and agent for service. The registration statement has not yet been declared effective, and the filing states that the preliminary prospectus "is not an offer to sell these securities." As an emerging growth company under the JOBS Act, the company is subject to reduced public company disclosure standards, as the filing describes.
What Was Disclosed
Turn Therapeutics filed a shelf registration statement on November 9, 2026, registering up to $150,000,000 in various securities and establishing an at-the-market common stock sales facility of up to $50,000,000 with TD Securities (USA) LLC.




Please wait processing your request...